Insider Buying: Cytosorbents Co. (NASDAQ:CTSO) CFO Purchases 20,000 Shares of Stock

Cytosorbents Co. (NASDAQ:CTSO) CFO Peter J. Mariani purchased 20,000 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was bought at an average price of $0.96 per share, for a total transaction of $19,200.00. Following the transaction, the chief financial officer now directly owns 401,363 shares in the company, valued at $385,308.48. This trade represents a 5.24 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Cytosorbents Price Performance

Shares of NASDAQ:CTSO opened at $0.86 on Thursday. Cytosorbents Co. has a 52 week low of $0.70 and a 52 week high of $1.97. The company has a 50-day moving average price of $0.96 and a 200 day moving average price of $1.02. The company has a market cap of $46.92 million, a P/E ratio of -2.38 and a beta of 0.57. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06.

Institutional Trading of Cytosorbents

Several hedge funds have recently modified their holdings of the business. CM Management LLC grew its holdings in Cytosorbents by 3.0% during the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock worth $598,000 after acquiring an additional 25,000 shares during the period. Geode Capital Management LLC lifted its holdings in Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after acquiring an additional 32,415 shares during the period. Atomi Financial Group Inc. purchased a new stake in shares of Cytosorbents during the 3rd quarter worth $51,000. Finally, Sargent Investment Group LLC boosted its position in shares of Cytosorbents by 4.9% during the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after purchasing an additional 67,181 shares in the last quarter. 32.87% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on CTSO shares. HC Wainwright reiterated a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a research note on Monday, November 11th. StockNews.com started coverage on shares of Cytosorbents in a research report on Thursday, December 12th. They issued a “hold” rating on the stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.